MP27: Prostate Cancer: Advanced (including Drug Therapy) I

Saturday, May 14, 2022

10:30 AM – 11:45 AM

Location: Room 222

Poster Session Moderator(s)

NS

Neal Shore, MD

Carolina Urologic Research Center
RK

Robert Karnes, MD

mayo clinic

Presentations:

10:30 AM – 11:45 AM

MP27-01: Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer
Poster Presenter: Pär Stattin
10:30 AM – 11:45 AM

MP27-02: Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates For Adjuvant Radiotherapy Among Patients With Adverse Pathology at radical Prostatectomy
Poster Presenter: Elio Mazzone
10:30 AM – 11:45 AM

MP27-03: Delaying Post-Operative Radiation Therapy After Radical Prostatectomy Is Associated With Increased Functional Outcomes: Results From A Large Single, Referral Center Series
Poster Presenter: Mario de Angelis
10:30 AM – 11:45 AM

MP27-04: Oncologic Outcomes in Men with Adverse Pathology and Biochemical Persistence After Radical Prostatectomy
Poster Presenter: Benjamin Beech, MD, FRCSC
10:30 AM – 11:45 AM

MP27-05: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-resistant Prostate Cancer Patients With and Without Prior Local Therapy With Radical Prostatectomy or Radiotherapy
Poster Presenter: D. Robert Siemens, MD,FRCSC – Kingston General Hospital
10:30 AM – 11:45 AM

MP27-06: Characteristics and progression-freesurvival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer (mHSPC) at the time of diagnosis.
Poster Presenter: Laurent Brureau
10:30 AM – 11:45 AM

MP27-07: Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world multicenter analysis
Poster Presenter: Taku Naiki, MD, PHD – Nagoya City University
10:30 AM – 11:45 AM

MP27-08: Evaluating the efficacy of a novel AKR1C3 inhibitor in patient-derived prostate cancer cell line and xenograft models
Poster Presenter: Chengfei Liu, MD, PHD – University of California, Davis
10:30 AM – 11:45 AM

MP27-09: Impact of trough concentrations of abiraterone and D4A on the clinical outcomes of patients with metastatic castration-sensitive and castration-resistant prostate cancer
Poster Presenter: Yoshiko Takahashi, MD – Akita
10:30 AM – 11:45 AM

MP27-10: Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape
Poster Presenter: Jacqueline Reedy Griffin, PhD,MS
10:30 AM – 11:45 AM

MP27-11: Increased cytokine gene expression and inflammatory markers associated with androgen deprivation therapy
Poster Presenter: Sanjay Gupta, PHD – Case Western Reserve University
10:30 AM – 11:45 AM

MP27-12: Development of Exosome-based Plasma RNA Biomarkers for High-Risk Prostate Cancer
Poster Presenter: Sandra Marlene Gaston, PhD
10:30 AM – 11:45 AM

MP27-13: Long-term Safety of Darolutamide Among Patients With Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy
Poster Presenter: Robert Jones, MD,PhD – Velindre Hospital
10:30 AM – 11:45 AM

MP27-14: Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial
Poster Presenter: Neal D. Shore, MD
10:30 AM – 11:45 AM

MP27-15: Sabizabulin has both cytotoxic and cytostatic activity in Phase 1b/2 clinical of men with metastatic castration resistant prostate cancer who progressed on androgen receptor targeting agents
Poster Presenter: Mark Markowski
10:30 AM – 11:45 AM

MP27-16: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study
Poster Presenter: Neal D. Shore, MD
10:30 AM – 11:45 AM

MP27-17: Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 2 QUEST Study
Poster Presenter: Ronald Francis Tutrone, MD – Chespaeake Urology Associates
10:30 AM – 11:45 AM

MP27-18: Practice Patterns in Management of Hormone Sensitive Metastatic and Castrate-Resistant Non-Metastatic Prostate Cancer
Poster Presenter: Daniel Joyce, MD
10:30 AM – 11:45 AM

MP27-19: Comparative out-of-pocket costs of treatment options in privately insured patients with advanced prostate cancer
Poster Presenter: Daniel Joyce, MD
10:30 AM – 11:45 AM

MP27-20: Analyzing Medical Marijuana's Effect on Narcotic Pain Medication Consumption in Patients with Prostate Cancer
Poster Presenter: Young Son, DO